Core Viewpoint - 华领医药-B (02552) reported significant growth in sales and profitability, marking a successful transition to full commercialization of its product, 华堂宁, with strong performance in the healthcare market [1] Financial Performance - For the six months ending June 30, 2025, 华领医药 reported a net sales revenue of 217.4 million yuan, representing a year-on-year increase of 112% [1] - The sales volume of 华堂宁 reached 1.764 million boxes, showing a year-on-year growth of 108% [1] - The company achieved a profit of 1.1839 billion yuan in the first half of the year, marking its first profitable period [1] Operational Highlights - The company successfully transitioned to full commercialization of 华堂宁 in January 2025, leading to significant growth driven by its own sales team [1] - The expansion of medical insurance coverage has contributed to a substantial increase in prescription volumes in secondary and tertiary hospitals [1] - The gross profit margin improved to 54.2%, an increase of 7.7 percentage points compared to the same period last year, indicating enhanced operational efficiency [1] Strategic Changes - Following the termination of the exclusive promotion service agreement with Bayer, the company confirmed a one-time deferred income of 1.2435 billion yuan [1]
华领医药-B涨超5% 上半年首次实现盈利 华堂宁销售表现强劲